Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis

Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration... Abstract Antibody titer against malondialdehyde (MDA)-modified low-density lipoprotein (LDL) has been found to be associated with atherosclerosis, but it has not been established whether it would detect subjects with coronary artery disease (CAD). In the present study, receiver-operating characteristic (ROC) analysis was used to compare the diagnostic accuracy of the antibody titer against MDA-modified LDL and high-density lipoprotein (HDL) and LDL cholesterol levels in discrimination between subjects with (n=51) and without (n=35) angiographically verified 3-vessel CAD. As a result, the antibody titer against MDA-modified LDL was lower in subjects with CAD compared with subjects without CAD (p<0.0001). The area under the ROC plot was 0.822 (95% CI, 0.727 to 0.918) for the antibody titer and 0.769 (95% CI, 0.661 to 0.876) for the HDL cholesterol concentration. Both the antibody titer and the plasma HDL cholesterol level were more accurate markers of CAD than the LDL cholesterol level. As a conclusion, our results indicate that the antibody titer against MDA-modified LDL discriminates between subjects with widespread CAD and those without CAD similarly as the HDL cholesterol concentration. Moreover, the antibody titer against MDA-modified LDL is inversely correlated with the risk of severe CAD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Chemistry and Laboratory Medicine (CCLM) de Gruyter

Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis

Download PDF
4 pages

Loading next page...
 
/lp/de-gruyter/antibody-titer-against-malondialdehyde-modified-ldl-compares-with-hdl-32Jaw6b59X

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
Copyright © 2005 by the
ISSN
1434-6621
eISSN
1437-4331
DOI
10.1515/CCLM.2005.065
pmid
15899649
Publisher site
See Article on Publisher Site

Abstract

Abstract Antibody titer against malondialdehyde (MDA)-modified low-density lipoprotein (LDL) has been found to be associated with atherosclerosis, but it has not been established whether it would detect subjects with coronary artery disease (CAD). In the present study, receiver-operating characteristic (ROC) analysis was used to compare the diagnostic accuracy of the antibody titer against MDA-modified LDL and high-density lipoprotein (HDL) and LDL cholesterol levels in discrimination between subjects with (n=51) and without (n=35) angiographically verified 3-vessel CAD. As a result, the antibody titer against MDA-modified LDL was lower in subjects with CAD compared with subjects without CAD (p<0.0001). The area under the ROC plot was 0.822 (95% CI, 0.727 to 0.918) for the antibody titer and 0.769 (95% CI, 0.661 to 0.876) for the HDL cholesterol concentration. Both the antibody titer and the plasma HDL cholesterol level were more accurate markers of CAD than the LDL cholesterol level. As a conclusion, our results indicate that the antibody titer against MDA-modified LDL discriminates between subjects with widespread CAD and those without CAD similarly as the HDL cholesterol concentration. Moreover, the antibody titer against MDA-modified LDL is inversely correlated with the risk of severe CAD.

Journal

Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter

Published: Apr 1, 2005

Keywords: antibodies; coronary artery disease; high-density lipoprotein cholesterol; malondialdehyde-modified low-density lipoprotein; receiver-operating characteristic analysis

References

  • Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes A possible mechanism of foam cell formation
    Griffith
  • Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non - insulin - dependent diabetes mellitus
    Uusitupa
  • Autoantibodies against oxidized low - density lipoproteins in older stroke patients
    Cherubini
  • Autoantibodies against modified low - density lipoproteins in coronary artery disease
    Tornvall
  • Selective coronary arteriography A percutaneous transfemoral technique
    Judkins
  • Antibodies to oxidized LDL in relation to intima - media thickness in carotid and femoral arteries in - year - old subjectively clinically healthy men
    Hulthe
  • Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction Free Radic
    Schumacher
  • Autoantibody against oxidised LDL and progression of carotid atherosclerosis
    Salonen
  • Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease
    Lehtimaki
  • IL - links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis
    Binder
  • Is oxidized low - density lipoprotein present in vivo
    Herttuala
  • Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits
    Wiklund
  • Immunoglobulin M type of autoantibodies to oxidized low - density lipoprotein has an inverse relation to carotid artery atherosclerosis
    Karvonen
  • LDL immunization induces T - cell - dependent antibody formation and protection against atherosclerosis
    Zhou
  • Generation characterization , and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB - containing serum lipoproteins
    Hammer
  • Immunization of LDL receptor - deficient mice with homologous malondialdehyde - modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes
    Freigang